Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2867
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies ; volume:17 ; number:1 ; day:19 ; month:5 ; year:2017 ; pages:1-12 ; date:12.2017
Cancer cell international ; 17, Heft 1 (19.5.2017), 1-12, 12.2017
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Nasir, Aejaz
- Beteiligte Personen und Organisationen
-
Holzer, Timothy R.
Chen, Mia
Man, Michael Z.
Schade, Andrew E.
SpringerLink (Online service)
- DOI
-
10.1186/s12935-017-0427-5
- URN
-
urn:nbn:de:1111-2017052817594
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nasir, Aejaz
- Holzer, Timothy R.
- Chen, Mia
- Man, Michael Z.
- Schade, Andrew E.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Anti-angiogenic therapies in brain metastases
Anti-angiogenic therapies for advanced esophago-gastric cancer
VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment
Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update
Anti-angiogenic alternatives to VEGF blockade
Antiangiogenic therapies in ovarian cancer
Future options of anti-angiogenic cancer therapy
Correction: Beyond starving cancer: anti-angiogenic therapy
Characterization of anti-angiogenic therapy response in glioblastoma
Perforated Gastric Ulcer Associated with Anti-Angiogenic Therapy
Assessing metastasis risk after pre‐operative anti‐angiogenic therapy
Comparison of anti-angiogenic properties of pristine carbon nanoparticles
Anti-angiogenic therapies in brain metastases
Anti-angiogenic therapies for advanced esophago-gastric cancer
VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment
Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update
Anti-angiogenic alternatives to VEGF blockade
Antiangiogenic therapies in ovarian cancer
Future options of anti-angiogenic cancer therapy
Correction: Beyond starving cancer: anti-angiogenic therapy
Characterization of anti-angiogenic therapy response in glioblastoma
Perforated Gastric Ulcer Associated with Anti-Angiogenic Therapy
Assessing metastasis risk after pre‐operative anti‐angiogenic therapy
Comparison of anti-angiogenic properties of pristine carbon nanoparticles
Anti-angiogenic therapies in brain metastases
Anti-angiogenic therapies for advanced esophago-gastric cancer
VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment
Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update
Anti-angiogenic alternatives to VEGF blockade
Antiangiogenic therapies in ovarian cancer
Future options of anti-angiogenic cancer therapy
Correction: Beyond starving cancer: anti-angiogenic therapy
Characterization of anti-angiogenic therapy response in glioblastoma
Perforated Gastric Ulcer Associated with Anti-Angiogenic Therapy
Assessing metastasis risk after pre‐operative anti‐angiogenic therapy